Bryostatin 1 causes attenuation of TPA-mediated tumor promotion in mouse skin

NING ZENG, YI XU, YIPING WU, TANG HONGBO and MIN WU

Department of Plastics and Aesthetic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China

Received July 16, 2017; Accepted September 14, 2017

DOI: 10.3892/mmr.2017.7993

Abstract. The present study was designed to investigate the tumor inhibitory potential of bryostatin 1 in a 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse model of skin cancer. The radical inhibition potential of various doses of bryostatin 1 was investigated against 2,2-diphenyl-1-picrylhydrazyl (DPPH) bleach in vitro. The DPPH radical potential was observed compared with treatment with 5, 10, 15, 20, 25 and 30 µM doses of bryostatin 1. In vivo, bryostatin 1 prevented the TPA-mediated increase in the level of H₂O₂ and myeloperoxidase in mouse epidermal tissue. Pretreatment of the mice with bryostatin 1 (30 µM) followed by administration of TPA reduced the edema, as demonstrated via punched-out mouse ear tissue, to 7.2 mg, compared with 14 mg in the TPA-treated group. Treatment with bryostatin 1 prior to TPA administration markedly prevented the inflammation of the skin by inhibiting hyperplasia in the epidermal layer and the aggregation of inflammatory cells. The results demonstrated that treatment of mice with bryostatin 1 at a 30 µM dose prior to TPA administration significantly (P<0.005) inhibited the TPA-mediated increase in the level of COX-2. The activity of ornithine decarboxylase, increased by TPA, was additionally inhibited following pretreatment of the mice with bryostatin 1. In the mice treated with bryostatin 1 at 30 µM doses prior to the administration of TPA, the appearance of papillomas was 20%, compared with 100% in the TPA group. Mice pretreated with bryostatin 1 at 30 µM doses prior to TPA administration exhibited the appearance of 0.4 mean papillomas in each animal, compared with 5.2 in the TPA group. Therefore, the results of the present study demonstrated that bryostatin 1 inhibited the development and progression of tumors of skin in the mice, through the prevention of inflammation-inducing processes and the quenching of radicals. Therefore, bryostatin 1 maybe considered to be adrug of importance in the treatment of skin tumor.

Introduction

Cancer is considered to be a process with multiple stages, and carcinogenicity depends on various factors, including the extent of oncogene activation and tumor suppressor gene mutations. In addition carcinogenicity is governed by the duration of carcinogenic factor exposure (1,2). Different physiochemical agents are known to induce carcinoma in the skin of animals. The sequence of processes involved includes damage to skin, tissue inflammation, formation of hyperplasia, appearance of papillomas and subsequent squamous cell cancer (3-5). The induction of papillomas may be achieved by the administration of 12-O-tetradecanoylphorbol-13-acetate (TPA) to animal skin, which causes activation of oncogene transcribing factors, nuclear factor (NF)-κB and transcription factor AP-1 (AP-1) (6-8). Following the activation of NF-κB and AP-1, the rate of inflammatory processes, the initiation of cell proliferation and the production of papillomas are increased. Studies using models of skin carcinoma have led to the identification of various factors involved in the development and progression of skin tumor (3,4). The use of mouse models of skin carcinoma led to the investigation of the role of inhibitors of tumor induction and malignant transformation in skin cancer (5). The results of previous study revealed that bioactive natural products isolated from plants may possess potent skin and epithelial cancer prevention potential (9). The progression of tumors is enhanced by cellular oxidative stress and inflammatory reactions, which indicates that the inhibition of these processes is of importance for the treatment of cancer (10). Natural products isolated from organisms of marine origin additionally serve as the source of a number of therapeutically potent compounds (11). An example of such a molecule, bryostatin 1 (Fig. 1) is isolated from the invertebrate Bugulaneritina, which is a member of the Ectoprocta phylum (11). Biological investigation has revealed that bryostatin 1 aids in the development of the immune system in addition to causing a promotion of hematopoietic differentiation and stimulation (12). A previous study demonstrated that treatment with bryostatin 1 resulted in the inhibition of phorbol ester-mediated induction of carcinoma growth and proliferation (13). In ovarian carcinoma,
treatment with bryostatin 1 induced cell growth inhibition via the induction of apoptotic pathways (11,14). In hepatic cancer, renal cancer, melanoma and leukaemia cell lines, exposure to bryostatin 1 inhibited viability and induced apoptosis (14-16). Studies involving rat models of carcinoma have revealed that there is direct association between the in vivo and in vitro anti-tumor potential of bryostatin 1 (16). The present study was designed to investigate the tumor inhibitory tendency of bryostatin 1 in a TPA-induced mouse model of skin cancer. The results demonstrated that bryostatin 1 inhibited the development and progression of tumors of skin in mice through the prevention of inflammation-inducing processes and the quenching of radicals.

Materials and methods

Chemicals and reagents. Bryostatin 1, benzo[α]pyrene and TPA were supplied by Sigma-Aldrich (Merck KGaA, Darmstadt, Germany).

Animals. A total of 48 female 7-week old BALB/c nude mice (12-20 g) were obtained from the Animal Experiment Center of Beijing, China. The animals were housed in an animal facility center under conditions free of pathogens with 12 hourly light and dark cycle at 24°C with 30-70% humidity. All the mice were provided with access to food and water ad libitum. The animal experimental protocol was approved by the Animal Ethical Committee of Tongji Medical College of Huazhong University of Sciences and Technology (Wuhan, China).

Treatment strategy. The day prior to the administration of bryostatin 1, the animals were shaved on the upper side of the body to remove all hair. The bryostatin 1 (30 µM) was administered 10 min prior to the administration of TPA (7.2 mg). All animal protocols used in the present study were approved by the Committee of Experimental Animal Administration of the Second Military Medical University Laboratory (Shanghai, China).

Analysis of bryostatin 1 radical inhibition activity. For the determination of the radical inhibition activity of bryostatin 1, 2,2-diphenyl-1-picrylhydrazyl (DPPH) was used. From a 10-mM stock solution of DPPH in methanol alcohol, 30 µl was added to a tube containing various concentrations of bryostatin 1 (5, 10, 15, 20, 25 and 30 µM). Subsequently, 3 ml methyl alcohol was added to the tube, which was allowed to stand for 30 min. A total of 1 ml distilled water and 3 ml toluene was added to the tube, followed by centrifugation at 2,500 x g for 15 min at room temperature. The absorbance of the tube was measured three times independently at a wavelength of 517 nm.

In vivo radical inhibition activity of bryostatin 1. The animals were shaved on the upper side of the body one day prior to the start of the experiment. The following day, 200 µl 2-propanone was applied to the body surface, followed by the administration of 5 nmol TPA two times with an intervening gap of 24 h. The administration of 5 nmol TPA was performed either subsequent to pretreatment with bryostatin 1 or without bryostatin 1. Sacrifice of the mice was performed using pentobarbital sodium (3%), 2 h subsequent to the administration of the second TPA dose. The production of H2O2 induced by the administration of TPA, and its inhibition by bryostatin 1, was subsequently determined. For this purpose, the mouse epidermal layers were extracted and treated with a buffer solution consisting of potassium hydrogen phosphate (50 mM) and NaN3 (10 mM). The layers were subjected to homogenization using a Polytron homogenizer (Kinematica AG, Lucerne, Switzerland) followed by 15 min centrifugation at (2,500 x g) at 4°C. A 0.5-ml quantity of the collected supernatant was transferred to glass tubes, treated with phenol red (0.2 mg/ml) and subsequently subjected to incubation for 15 min at 37°C. 1N (normal) solution of sodium hydroxide (100 µl) was added to the tubes, followed by absorbance measurements at 612 nm. DMSO was used as control.

Skin myeloperoxidase (MPO) activity determination. Skin tissues, following extraction, were subjected to homogenization and treatment with a 0.5% solution of C6H13N (CH3)3 Br in 50 mM K2HPO4 buffer using the Polytron homogenizer. Following homogenization, the samples were centrifuged for 20 min at 4°C at 2,000 x g. A mixture of 4-aminophenylpyrine (25 mM), phenol (2%) and hydrogen peroxide (1.7 mM) was transferred to a glass tube. A total of 0.5 ml tissue suspension was added to the tube and mixed thoroughly. For each tube, the absorbance was measured at a wavelength of 460 nm. The activity of MPO in the skin tissue samples was expressed as units/g.

Determination of edema in mouse ear tissue. The mice in the untreated group were treated with TPA (7.2 mg) solution in 2-propanone into the right ear (6 mice/group). In the treatment group, mice were given bryostatin 1 prior to the application of TPA solution in 2-propanone, whereas those in the normal control group received normal saline. Following 8 h of TPA administration, the mice were sacrificed using pentobarbital sodium (3%) to extract an 8-mm ear-punch for biopsies. The samples were weighed to record the increased weight in the untreated group.

Analysis of ornithine decarboxylase activity. The extracted skin samples from the mice were kept in water for 45 sec at 60°C and subsequently transferred to ice-cold water. The epidermal layer of the skin was treated with 50 mM KH2PO4 buffer mixed with 2 mM dithiothreitol and 0.1 mM ethylene diamine tetra acetate. Homogenization of the epidermal layer was performed using the polytron homogenizer. The extracts were allowed to stand for 15 min at room temperature. The absorbance was measured at a wavelength of 517 nm.
Analysis of cyclooxygenase-2 (COX-2) activity. The epidermal layer was lysed using radioimmunoprecipitation assay buffer (Sigma-Aldrich, Merck KGaA) and a DCTM protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used for determination of the protein concentration in the samples. The extracted proteins (40 µg/lane) were loaded and separated in 15% SDS-PAGE gel and then transferred to polyvinylidene fluoride membranes. The non-specific sites in the membranes were blocked for 15 min at room temperature via treatment with non-fat dried milk (5%) in TBS with Tween-20 (TBS-T) buffer. Incubation with primary antibodies against COX-2 (1:500; cat. no. H-62; Santa Cruz Biotechnology Inc., Dallas, TX, USA) and α-tubulin (1:500; cat. no. TU-02; Santa Cruz Biotechnology Inc.) for 1 h at 4˚C was followed by washing with 4X TBS-T buffer. Membrane incubation was performed with horseradish peroxidase-conjugated anti-mouse immunoglobulin (1:10,000, cat. no. sc2005; Santa Cruz Biotechnology Inc.) for 1 h at 4˚C. Complexes formed by the interaction between proteins and antibodies were analyzed using an enhanced chemiluminescence detection system (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA).

Results

Bryostatin1 inhibits DPPH radical activity. The radical inhibitory potential of various doses of bryostatin 1 was investigated against DPPH bleach in vitro. With the increase in dosage of bryostatin1, a reduction was observed in the DPPH radical activity. The DPPH radical potential was reduced to 10, 37, 59, 71, 83 and 98%, respectively, at 5, 10, 15, 20, 25 and 30 µM doses of bryostatin 1 (Fig. 2).

Pretreatment with Bryostatin1 prevents the TPA-mediated increase in the level of H2O2 and the activity of MPO. Administration of TPA to the mice at a concentration of 5 nmol twice, with an intervening gap of 24 h, led to a 3-fold increase in the H2O2 level in the epidermal layer compared with normal mice (Fig. 3). However, treatment of the mice with bryostatin1 prior to TPA administration prevented the increase in the level of H2O2 in the mouse epidermal layer. The H2O2 inhibition level was observed to be 3, 2.2, 1.8, 1.3, 1.2 and 1-fold higher in the mice following treatment with 5, 10, 15, 20, 25 and 30 µM, respectively, bryostatin 1. Administration of TPA to the mice at a concentration of 5 nmol twice, with an intervening gap of 24 h, led to a 30-fold increase in MPO activity compared with normal mice (Fig. 4). Treatment with bryostatin 1 prior to TPA administration at doses of 5, 10, 15, 20, 25 and 30 µM, respectively, reduced the level of MPO activity in a dose dependent manner.
Bryostatin 1 prevents edema of the ear and skin inflammation caused by TPA administration in mice. In mice administered with 5 nmol doses of TPA twice, with an intervening gap of 24 h, edema formation was observed in the ear. The mean weight of the extracted edema masses from the mouse ears was recorded to be 14 mg. However, in mice pretreated with bryostatin 1 at doses of 5, 10, 15, 20, 25 and 30 µM, the edema ear masses were recorded to be 14, 12, 10, 9, 8 and 7.2 mg, respectively (Fig. 5). Administration of TPA to the mice for one week at a 5-nmol dose caused hyperplasia in the epidermal layer and aggregation of inflammatory cells leading to increased skin thickness. Treatment of the mice with bryostatin 1 prior to TPA administration markedly prevented inflammation of the skin by inhibiting hyperplasia in the epidermal layer and the aggregation of inflammatory cells (Fig. 6). At a 30-µM concentration of bryostatin 1, inflammation of the skin in the mice was completely prevented.

Bryostatin 1 inhibits the TPA-mediated increased level of COX-2. The mice administered with TPA exhibited marked increased levels of the protein COX-2 compared with the normal group. However, treatment of the mice with bryostatin 1 prior to TPA administration at a dosage of 30 µM inhibited the TPA-mediated increase in the level of COX-2 (Fig. 7).

Bryostatin 1 inhibits the TPA-mediated increased activity of ornithine decarboxylase. The activity of ornithine decarboxylase was increased markedly in TPA-administered
mice compared with the control. However, when mice were treated with bryostatin 1 prior to TPA administration at a dosage of 30 µM, the activity of ornithine decarboxylase in the epidermal layer was significantly inhibited. At 5, 10, 15, 20, 25 and 30 µM doses of bryostatin 1, the activity level of ornithine decarboxylase was reduced to 1,150, 900, 630, 340, 290 and 240, respectively, compared with 1,200 in TPA group (Fig. 8).

**Bryostatin 1 inhibits TPA-mediated increase in progression of tumor in mouse.** Examination of the mice 3 months subsequent to the administration of TPA demonstrated the appearance of papillomas in all animals. In the mice treated with bryostatin 1 at 30-µM doses prior to TPA administration, the appearance of the papillomas was 20% at 2 months. Determination of papilloma multiplicity revealed 5.2 papillomas on average in all the mice administered with TPA. In the mice pretreated with bryostatin 1 at 30-µM doses prior to TPA administration, the mean papilloma number in each animal was observed to be 0.4 (Fig. 9).

**Discussion**

The present study demonstrated the effect of bryostatin 1 on the progression of tumors of the skin in TPA-induced model skin cancer. The results demonstrated that bryostatin 1 inhibited the progression of skin tumor in mice by suppressing the activity of ornithine decarboxylase and reducing the level of COX-2. A previous study revealed that damage to tissues caused by the onset of inflammatory reactions is associated with the progress of carcinoma (18). The transduction of inflammatory signals leads to an aggregation of immune cells and subsequent expression of radicals at the site of inflammation, which in turn destroy cellular components, including chromatin and membranes (19). Therefore, radical species serve an important role in the development and progression of cancer. In view of these findings, it is evident that compounds which are able to quench radicals and inhibit inflammatory reactions may be of value for the treatment of carcinoma. The present study illustrated that bryostatin 1 exhibited anti-oxidative potential *in vitro* and *in vivo*. Bryostatin 1 inhibited the radical activity of DPPH completely at a 30-µM dose *in vitro*. *In vivo*, pretreatment with bryostatin 1 prevented the formation of H$_2$O$_2$ in the epidermal layer of TPA-mediated skin tumor model mice. The expression of myeloperoxidase in
the epidermal layer of skin tumor model mice represents the production of radicals (20). The results of the present study demonstrated that pretreatment with bryostatin 1 inhibited the expression of myeloperoxidase in TPA-treated mice. It has been reported that prostaglandin formation from arachidonic acid is catalyzed by the enzyme COX (21). It is known that COX-2 expression is enhanced by various factors, including toxic secretions from bacteria, tumor promoting agents and pro-inflammatory cytokines (22,23). An increased level of COX-2 leads to the onset of inflammatory reactions and promotes tumor progression (24). Therefore, it has been proposed that diminishing the expression of COX-2 may be of therapeutic value for the prevention of inflammation (24). The present study demonstrated that mice administered with TPA exhibited marked increased level of the protein COX-2. However, treatment of the mouse with bryostatin1 prior to TPA administration inhibited the TPA-mediated increase in the level of COX-2. Inflammation of tissues results in the promotion of ornithine decarboxylase activity, which subsequently serves an important role in the progression of skin tumors in mice (25). Ornithine decarboxylase, on activation, catalyzes the formation of polyamine in cells which promotes the development of tumors (25). The results of the present study demonstrated marked increase in the activity of ornithine decarboxylase in the TPA-treated mice. However, treatment with bryostatin 1 prior to TPA administration in habitated he activity of ornithine decarboxylase in the epidermal layer. Compounds derived from plants are being evaluated for therapeutic value against various disorders, with the aim of developing novel and efficient treatment strategies (26). The results of the present study revealed that bryostatin 1 reduced the number of papillomas in each mouse in addition to the number of mice with papillomas. Therefore, bryostatin 1 exhibited the potential to act as a chemo preventive agent against skin tumor development.

In conclusion, bryostatin 1 inhibited the development and progression of tumors of the skin in mice through the prevention of inflammation-inducing processes and the quenching of radicals. Therefore, bryostatin 1 may be suggested to exert an important role in the treatment of skin tumor.

References